Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

e Cancer Center, University of Iowa, USA (Principal Investigator, USA)

SPC2996 was given by intravenous infusion on 6 repeated occasions over a two week period. Five different dosage levels were investigated. At the top dose of 4mg/kg/infusion, all 6 of the 6 patients studied showed a decrease in the severity of their leukaemia, with a rapid reduction in the numbers of circulating lymphocytes (white blood cells) being observed within 24 hours of the first administration of the drug. Five out of the 6 patients in this group showed a maximal reduction in lymphocyte count of 50% or more, indicating a clinically beneficial effect. See figure 1 attached.

A dose response to drug was also observed with patients treated with SPC2996 at 2 mg/kg/infusion having a transient reduction in lymphocytes of up to 30% and doses of 1 mg/kg/infusion having no effect.

Reductions in lymph node swelling was also observed in these patients, 2 out of 4 patients receiving drug at 4mg/kg/infusion and 1 out of 4 at 2 mg/kg/infusion showed a reduction in lymph node diameters of 50% or more. Overall, using standard clinical assessment procedures, 2 of the 6 patients treated with the top dose of drug showed a partial tumour response, one of 28-42 days and one of more than 182 days, and 3 patients had stable disease for periods of between 28 and 70 days. Mean time to disease progression was approximately twice as long (122 days) in the group receiving drug at 4mg/kg/infusion as in the groups receiving 2 or 1mg/kg/infusion (42 and 79 days).

Mechanism of Action

In cell culture and experimental models of disease, SPC2996 inhibits the production of the protein Bcl-2 and its beneficial effects in patients are thought to be due to the drug reducing Bcl-2 levels within cancerous CLL lymphocytes by binding specifically to and inactivating the messenger RNA for Bcl-2. High levels of Bcl-2 in CLL cells are associated with resistance to cancer cell death and poor disease ou
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
(Date:5/23/2013)... 2013   BioLife Solutions , Inc. (OTC:BLFS), a ... hypothermic storage and cryopreservation freeze ... media manufacturer , today announced its participation at the ... 2013 this week in London ... Dr. Aby J. Mathew, BioLife,s Senior Vice President and ...
(Date:5/23/2013)... TOKIO , 22. Mai 2013 ... Weiteren Ranbaxy), eine Tochtergesellschaft von Daiichi ... Sankyo), gab am 22. Mai die ... letzten Jahren ergriffen hat, um sich ... ( http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html ). ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Ranbaxy kündigt Verbesserungen bei Geschäftsstandards und Qualitätssicherungsinitiativen an 2
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Acid Testing Market--New Product Development ... For Instrument and Reagent Suppliers ...
... NEW YORK, June 20, 2011 Reportlinker.com ... is available in its catalogue: ... 2011 http://www.reportlinker.com/p0558499/Top-Medical-Devices-and-Imaging-Technologies-2011.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices ... medical device and imaging technologies that have ...
Cached Medicine Technology:Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 2Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 3Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 4Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 5Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 6Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 7Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 8Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 9Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 10Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 11Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 12Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 13Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 14Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 15Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers 16Reportlinker Adds Top Medical Devices and Imaging Technologies 2011 2
(Date:5/23/2013)... (PRWEB) May 23, 2013 NDI ... funds and develops innovative neurodevice technologies, has launched ... (DBI). DBI will commercialize its groundbreaking technology ... (DBS) therapy for patients with Parkinson’s disease. ... Parkinson’s disease and generates more than $275 million ...
(Date:5/23/2013)... little was scientifically known about the human potential to ... people who are suffering in a way that motivates ... at the Center for Investigating Healthy Minds at the ... adults can be trained to be more compassionate. The ... Science , is the first to investigate whether training ...
(Date:5/23/2013)... connections in the brains of people affected by ... Peter Williamson, from Western University, to gain a ... important diseases. Dr. Williamson and colleagues have ... are disrupted in different psychiatric diseases. These ... Meeting, the annual meeting of the Canadian Association ...
(Date:5/23/2013)... DRE, Inc. is now offering the DRE ... upgrade older model DRE or BFW halogen headlights to ... , DRE and BFW customers can easily and affordably ... to LED with DRE’s American-made Xavier-C3 LED headlight conversion ... a bright, clean and even field of illumination with ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... to announce the launch of Current Digital, a ... web development and digital marketing needs. Companies now ... a strategic business necessity. This can often leave ... creative strategy on preselected software platforms that they ...
Breaking Medicine News(10 mins):Health News:NDI Launches Deep Brain Innovations, LLC 2Health News:NDI Launches Deep Brain Innovations, LLC 3Health News:Study shows people can be trained to be more compassionate 2Health News:Study shows people can be trained to be more compassionate 3Health News:Study shows people can be trained to be more compassionate 4Health News:Researchers identify networks of neurons in the brain that are disrupted in psychiatric disease 2Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 2Health News:New DRE, Inc. LED Conversion Kit Allows Doctors to Upgrade Older Halogen Technology Without Replacing Entire Lighting Systems 3Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3
... in French . ,OTTAWA (June ... Health, announced today that the Government of Canada is ... principal medical isotope affected by the current shutdown at ... isotopes in combination with imaging technologies to diagnose and ...
... Extending health insurance coverage to all children in the ... benefits that are greater than the costs, according to ... Public Policy. "Providing health insurance to all children ... Ho, chair in health economics at the Baker Institute ...
... Association for Molecular Pathology (AMP) today released the text ... Federal Coordinating Council for Comparative Effectiveness Research (CER) in ... on which to focus CER activities. "CER is ... makers who see it as a method to examine ...
... season will soon arrive in the Asian territories and culicine ... the virus that causes Japanese Encephalitis (JE), which kills 10-15,000 ... the largest provider of travel medical services in the U.S. ... FDA, and is ready for distribution in the United States. ...
... (Nasdaq: BMRN ) announced today that the temporary ... is not expected to have any impact on Aldurazyme supply ... fill at the Allston Landing facility was in September 2008. ... vialed inventory on hand, utilizes a second fill finish supplier ...
... CRYSTAL, Minn., June 16 On June 4, 2009, Herzing University ... to begin a Bachelor of Science in Nursing ... of preparation. , , A new medical lab, extensive ... few of the additions brought to campus to prepare for the ...
Cached Medicine News:Health News:Providing health insurance for US children would be cheaper than expected, study says 2Health News:AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research 2Health News:AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research 3Health News:Monsoon Season will Bring Japanese Encephalitis 2Health News:Temporary Production Interruption at Allston Landing Manufacturing Facility Has No Impact on Aldurazyme 2Health News:Herzing University, Minneapolis Receives Board of Nursing Approval 2
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Colorado Microneedles offer the surgeon precision in cutting and coagulation, without the expense and inconvenience of a laser. The needles may also be used for dissecting large areas such as the sca...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: